Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | BCL9 | O00512 | 1/20 | 0.54 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.49 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.49 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7477346 | 0.87 | HTR2A (0.54) | HTR2ABCL9CTNNB1GAAPTPN7 | |
| SCHEMBL409598 | 0.86 | HTR2A (0.59) | HTR2ABCL9CTNNB1GAAPTPN7 | |
| SCHEMBL5526504 | 0.85 | HTR2A (0.58) | HTR2ABCL9CTNNB1GAAPTPN7 | |
| SCHEMBL20466168 | 0.84 | HTR2A (0.52) | HTR2ABCL9CTNNB1GAAPTPN7 | |
| SCHEMBL12064910 | 0.84 | HTR2A (0.52) | HTR2ABCL9CTNNB1GAAPTPN7 | |
| SCHEMBL26374 | 0.84 | GAA (0.65) | HTR2ABCL9CTNNB1GAAPKM | |
| SCHEMBL25764 | 0.83 | HTR2A (0.57) | HTR2ABCL9CTNNB1GAAPTPN7 | |
| SCHEMBL763025 | 0.83 | HTR2A (0.57) | HTR2ABCL9CTNNB1GAAPTPN7 | |
| SCHEMBL13069276 | 0.83 | HTR2A (0.57) | HTR2ABCL9CTNNB1GAAPTPN7 | |
| SCHEMBL1421471 | 0.83 | HTR2A (0.57) | HTR2ABCL9CTNNB1GAAPTPN7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4294813-B1 | TETRACYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20250214931-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Cadrenal Therapeutics, Inc. | 2025-07-03 | — | — | US | disclosed |
| US-20250144230-A1 | LINKERS FOR USE IN ANTIBODY DRUG CONJUGATES | ORUM THERAPEUTICS, INC. (KR) | 2025-05-08 | — | — | US | disclosed |
| WO-2025080689-A1 | LIPID PRODRUGS OF BROMOLYSERGIDE AND USES THEREOF | SEAPORT THERAPEUTICS, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| CN-119522222-A | Nitrogen-containing heterocyclic compound, preparation method thereof, intermediate thereof and application thereof | 上海艾力斯医药科技股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
| EP-4509184-A2 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas Operations, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| US-20250034096-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2025-01-30 | — | — | US | disclosed |
| EP-3526202-B1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS INC (US) | 2025-01-08 | — | — | EP | disclosed |
| WO-2024238872-A2 | ISOINDOLINONE-GLUTARIMIDE ANTIBODY CONJUGATES, AND USES THEREOF | FIREFLY BIO, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| US-12084414-B2 | Therapeutic compounds and compositions | EXITHERA PHARMACEUTICALS, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| WO-2002100347-A2 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-20020151529-A1 | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration | XENOPORT, INC. | 2002-10-17 | — | — | US | disclosed |
| WO-2002028881-A1 | BILE-ACID DERIVED COMPOUNDS FOR PROVIDING SUSTAINED SYSTEMIC CONCENTRATIONS OF DRUGS AFTER ORAL ADMINISTRATION | XENOPORT, INC. (US) | 2002-04-11 | — | — | WO | disclosed |
| US-6265418-B1 | ANTICOAGULANTS | UBE INDUSTRIES, LTD. (JP) | 2001-07-24 | — | — | US | disclosed |
| EP-1020467-A1 | N-ACYLAMINO ACID AMIDE COMPOUNDS AND INTERMEDIATES FOR PREPARATION THEREOF | UBE INDUSTRIES LIMITED (JP) | 2000-07-19 | — | — | EP | disclosed |
| EP-0830372-A1 | CYCLIC PRODRUGS OF PEPTIDES AND PEPTIDE NUCLEIC ACIDS HAVING IMPROVED METABOLIC STABILITY AND CELL MEMBRANE PERMEABILITY | THE UNIVERSITY OF KANSAS (US) | 1998-03-25 | — | — | EP | disclosed |
| WO-1997039024-A1 | CYCLIC PRODRUGS OF PEPTIDES AND PEPTIDE NUCLEIC ACIDS HAVING IMPROVED METABOLIC STABILITY AND CELL MEMBRANE PERMEABILITY | THE UNIVERSITY OF KANSAS (US) | 1997-10-23 | — | — | WO | disclosed |
| EP-0167451-B1 | A NEW PROCESS FOR PREPARING NOVEL N-(ACYLOXY-ALKOXY) CARBONYL DERIVATIVES USEFUL AS BIOREVERSIBLE PRODRUG MOIETIES FOR PRIMARY AND SECONDARY AMINE FUNCTIONS IN DRUGS | MERCK & CO. INC. (US) | 1990-10-03 | — | — | EP | disclosed |
| US-4916230-A | Process for preparing novel N-(acyloxy-alkoxy)carbonyl derivatives useful as bioreversible prodrug moieties for primary and secondary amine functions in drugs | MERCK & CO., INC. (US) | 1990-04-10 | — | — | US | disclosed |
| EP-0167451-A2 | A new process for preparing novel N-(acyloxy-alkoxy) carbonyl derivatives useful as bioreversible prodrug moieties for primary and secondary amine functions in drugs | MERCK & CO. INC. (US) | 1986-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151529-A1 | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration | SLC10A2, SLC10A1, ABCB11 | HTR2A 2906/4885BCL9 2071/4885CTNNB1 3882/4885 |
| US-12084414-B2 | Therapeutic compounds and compositions | KLK5, KLKB1, KLK2 | HTR2A 4104/4885BCL9 2071/4885CTNNB1 3511/4885 |
| US-20250034096-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | HTR2A 1200/4885BCL9 1369/4885CTNNB1 1742/4885 |
| US-20250144230-A1 | LINKERS FOR USE IN ANTIBODY DRUG CONJUGATES | CD2BP2, CD47, EPCAM | HTR2A 4235/4885BCL9 30/4885CTNNB1 4513/4885 |
| US-20250214931-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | KLK5, KLKB1, KLK2 | HTR2A 4104/4885BCL9 2071/4885CTNNB1 3511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.